And we’re off on the infamous ASH DASH…
Atlanta Centennial Olympic Park
The annual data drop for the American Society of Hematology (ASH) meeting in Atlanta, Georgia is finally here.
Each year we write a series of in-depth previews ahead of the event exploring different aspects of hematologic malignancies in terms of what’s important, what to watch out for, and also key abstracts that may (or may not) have an impact.
This year we kick off the first of our series with a look at aggressive lymphomas and novel therapies in development including CAR T cell therapies, antibodies, ADCs and targeted therapies. There are some surprsies (of course) and also some potentially interesting relationships and consequences to consider.
To learn more insights on this intriguing topic, subscribers can log-in or you can click to gain access to BSB Premium Content.
It was only five years ago that the number of abstracts on CAR T cell therapies at the American Society of Hematology (ASH) ran to a dozen or less. Fast forward to 2016 and we now have tens of them, almost too many to count, let along review quickly and easily.
A scene from ASH 2015…
To give you an idea of the staggering speed of progress, in 2010 it took me less than half an hour to search and read all the CAR T cell abstracts, now it takes nearly a whole day to peruse and review them carefully.
We can’t resist a challenge…
As usual, we will write in more depth from the meeting as the data emerges in real time since many of the abstracts are often placeholders with updated information provided at the conference itself.
For now, here we provide an in-depth preview of the CAR T cell landscape in terms of the players, the products, new scientific research, biomarkers, emerging trends and more in a handy What to Watch For (W2W4) guide on key areas to expect at ASH to enable better enjoyment and awareness as the data rolls out next month.
Subscribers can log-in to learn more insights and which highlights matter…
Cell therapy is one of the hottest topics in cancer immunotherapy; however, it remains a field still in it’s infancy as companies and researchers work on strategies and concepts to increase efficacy and overcome resistance. The strategic landscape is still being defined. In cell therapy the ultimate winner may not be the company that is first to market.
Drs Seth Ettenberg and Michael Vasconcelles, Unum at #ASH15
In this post, we’re continuing this week’s theme of posts around novel cell therapies. Unum Therapeutics is a company that is no doubt already on your radar if you are into CAR-T cells.
Back at ASH 2015, I had the pleasure of interviewing Dr Seth Ettenberg (CSO) on the left and Dr Michael Vasconcelles (CMO) on the right.
We talked about what differentiates their approach from others in the CAR T cell space.
Subscribers can log in.